HU
Humacyte, Inc.
HUMAW · NASDAQ
$0.00 -99.09% (-$0.23)
1M -87.14%
Market Cap $2.53M
P/E Ratio -
Div. Yield -
ROE 938.20%
Piotroski F-Score Weak
2/9Valuation
100 /100
Cheap P/B 0.08x
P/S 1.19x
P/FFO N/A
Growth
49 /100
Stable Book val. growth 70.15%
Rev. growth 9.20%
FCF growth N/A
Profitability
0 /100
Weak Op. margin 5,240.78%
Gross margin 666.81%
FCF margin 4,599.72%
Quality
0 /100
Poor ROA 70.05%
ROIC 89.17%
Asset turnover 0.02x
Debt
30 /100
High Int. coverage -8.39x
Debt/Equity 2.12x
Current ratio 6.21x
Stability
1 /100
Unstable Profitable years 0
Beta 2.43x
EPS volatility 477.33%
Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe
Întreabă StockBot despre HUMAW
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Laura E. Niklason
Employees
184
Headquarters
Durham
Evenimente viitoare
06 NOV.
Earnings
Upcoming earnings report